{"pmid":32440985,"title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","Intern Emerg Med","Allione, Attilio","Giamello, Jacopo Davide","Paglietta, Giulia","Bernardi, Sara","Cavalot, Giulia","32440985"],"journal":"Intern Emerg Med","authors":["Allione, Attilio","Giamello, Jacopo Davide","Paglietta, Giulia","Bernardi, Sara","Cavalot, Giulia"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440985","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11739-020-02373-5","e_drugs":["Heparin"],"topics":["Treatment"],"weight":1,"_version_":1667523504850862080,"score":9.490897,"similar":[{"pmid":32378044,"pmcid":"PMC7201114","title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","Intern Emerg Med","Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","32378044"],"journal":"Intern Emerg Med","authors":["Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378044","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s11739-020-02358-4","keywords":["covid-19","heparin","treatment"],"e_drugs":["Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666262687609257984,"score":126.38747},{"pmid":32297089,"pmcid":"PMC7157827","title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.","The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment.","Intern Emerg Med","Testa, Sophie","Paoletti, Oriana","Giorgi-Pierfranceschi, Matteo","Pan, Angelo","32297089"],"abstract":["The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment."],"journal":"Intern Emerg Med","authors":["Testa, Sophie","Paoletti, Oriana","Giorgi-Pierfranceschi, Matteo","Pan, Angelo"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297089","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s11739-020-02331-1","keywords":["covid-19","doac","lmwh","sars-cov-2","vka"],"e_drugs":["Vitamin K","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138493291593728,"score":121.12005},{"pmid":32470198,"title":"Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.","text":["Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.","I thank Lindahl and Li for their thoughtful comments on the non-anticoagulant properties of heparin.(1) Heightened awareness of hypercoagulability has made heparin part and parcel of the COVID-19 management algorithms. In addition, reports of prophylactic anticoagulation failure have triggered several trials where escalated doses of heparin are compared with standard doses with the aim of preventing thrombotic complications. At this juncture, we do need to consider where do the non-anticoagulant properties of heparin fit in the COVID-19 clinical context?","J Thromb Haemost","Thachil, Jecko","32470198"],"abstract":["I thank Lindahl and Li for their thoughtful comments on the non-anticoagulant properties of heparin.(1) Heightened awareness of hypercoagulability has made heparin part and parcel of the COVID-19 management algorithms. In addition, reports of prophylactic anticoagulation failure have triggered several trials where escalated doses of heparin are compared with standard doses with the aim of preventing thrombotic complications. At this juncture, we do need to consider where do the non-anticoagulant properties of heparin fit in the COVID-19 clinical context?"],"journal":"J Thromb Haemost","authors":["Thachil, Jecko"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470198","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jth.14933","topics":["Treatment"],"weight":1,"_version_":1668167110008766464,"score":56.386936},{"pmid":32408391,"title":"Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.","text":["Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients.","Most severe manifestations of COVID-19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D-dimer [1]. A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID-19 patients with elevated D-dimer; similar preliminary results have been reported elsewhere [3]. A mounting body of evidence shows that SARS-CoV-2 causes a \"cytokine storm\" [1,4] that activates the coagulation cascade, leading to thrombosis. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [5].","J Thromb Haemost","Menezes-Rodrigues, Francisco Sandro","Padrao Tavares, Jose Gustavo","Pires de Oliveira, Marcelo","Guzella de Carvalho, Rafael","Ruggero Errante, Paolo","Omar Taha, Murched","Fagundes, Djalma Jose","Caricati-Neto, Afonso","32408391"],"abstract":["Most severe manifestations of COVID-19 cases, such as multiple organ failure and death, have been linked to coagulation dysfunction markers, such as platelet reduction and increases in prothrombin time, fibrin degradation products and, mainly, D-dimer [1]. A recent paper by Tang et al. [2] in this journal reported that heparin treatment reduced mortality of COVID-19 patients with elevated D-dimer; similar preliminary results have been reported elsewhere [3]. A mounting body of evidence shows that SARS-CoV-2 causes a \"cytokine storm\" [1,4] that activates the coagulation cascade, leading to thrombosis. Similar to the findings in severe sepsis, generalized deposition of intravascular thrombi compromises the blood supply of several organs, leading to organ failure [5]."],"journal":"J Thromb Haemost","authors":["Menezes-Rodrigues, Francisco Sandro","Padrao Tavares, Jose Gustavo","Pires de Oliveira, Marcelo","Guzella de Carvalho, Rafael","Ruggero Errante, Paolo","Omar Taha, Murched","Fagundes, Djalma Jose","Caricati-Neto, Afonso"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32408391","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1111/jth.14902","topics":["Treatment"],"weight":1,"_version_":1666802845275389952,"score":51.482105}]}